Testing pathogen-reduced red blood cells in people with or without antibodies
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study checks if a special treatment to reduce germs in red blood cells is safe for patients who may have developed antibodies from past transfusions. You will receive a small transfusion of these treated cells to see how your body reacts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 4 years old.
- You have had a blood transfusion before.
- It has been more than 120 days since your last transfusion with study red blood cells.
- You do not have any medical condition that makes a transfusion risky, like active bleeding or a weak immune system.
- You are not taking certain medications that affect red blood cell health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
This study tests a special way to label your own red blood cells so doctors can track how long they survive in your body. It helps improve how we measure blood cell recovery after transfusion.
This trial tests a new device called the ABTest Card that checks your blood type from a finger prick. It may help make blood transfusions safer and faster for people who need them.
This study is testing a new device that checks your blood type before a transfusion. It is designed for adults who need blood and for newborns who need routine blood tests.
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
This trial tests isatuximab (an anti-CD38 antibody) to help people who, after an allogeneic stem cell transplant with a major blood-type mismatch, keep needing ongoing red blood cell transfusions. It focuses on preventing or improving a condition called PRCA (a type of pure red blood cell aplasia) when the immune system isn’t producing enough new red blood cells.
Hear when a new Transfusion Reaction, Hemolytic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.